<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:11pt Arial, sans-serif; }
 .font2 { font:10pt Times New Roman, serif; }
 .font3 { font:15pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font3">JPMorgan</span></p>
<p><span class="font0" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.2hao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.2hao@jpmorgan.com</span></a></p>
<p><a name="bookmark0"></a><span class="font1" style="font-weight:bold;"><a name="bookmark1"></a>1H16 results takeaways</span></p>
<ul style="list-style:none;"><li>
<p><span class="font2" style="font-weight:bold;">1) &nbsp;&nbsp;&nbsp;1H16 sales &amp;&nbsp;profit grew by 17% YoY and 15% YoY, respectively: </span><span class="font2">Pharma sales grew by 20% YoY, of which its cardiovascular portfolio was up 48% Y/Y, CNS up 26%, metabolism and GI up 13%, anti-infective up 31%, oncology up 22%, and APIs/intermediates up 19% YoY. Sales of its 19 major products (with sales more than RmblOOmn each) grew by 26% YoY in 1H16. Gross margin expanded by 300bps YoY to 53.3%, thanks to the faster growth of high margin products such as You Di Er and You Li Tong (&gt;100% growth).</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;">2) &nbsp;&nbsp;&nbsp;Healthcare sendee business will continue to grow. </span><span class="font2">Hospital service sales grew by 12% YoY in 1H16. Now Fosun has 3,018 beds in operation in Fuoshan, Yueyang, Xuqing, Wenzhou, Xuzhou, Hefei, Taizhou, Yulin and Qingdao. According to management, the business will expand in 1<sup>st</sup> tier cities - e.g. Shanghai and Beijing - to tap on high-end customers and will establish specialist clinics for blood dialysis and gynecological examinations, in addition to its existing focus on general-purpose hospitals in 2<sup>nd</sup>/3<sup>rd</sup> cities.</span></p></li>
<li>
<p><span class="font2">3)</span><span class="font2" style="font-weight:bold;"> &nbsp;&nbsp;&nbsp;R&amp;D expenses on innovative drugs will increase. </span><span class="font2">Currently, innovative drugs and generic drugs accounted for 30% and 70% of total R&amp;D expenses. Management expects R&amp;D for innovative drugs to increase and will reach a 50:50 basis. Total R&amp;D expenses will also be &gt;5% of its pharma sales to maintain the company’s competitiveness. As of August, Fosun obtained eight production approvals and 10 INDs (Investigable New Drugs). Novel drug furuitinib (or SAF-189s) has moved into combined Phase 1-2 for ALK-positive NSCLC, while HLX07, bevacizumab, and cetuximab are cleared to commence human trials. Fosun has the most complete portfolio of biosimilars in China that are going through comparison studies with reference products.</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;">4) &nbsp;&nbsp;&nbsp;Major new products won most tenders in 1H16. </span><span class="font2">According to management, as major new products won most tenders, revenue from new products have grown significantly in 1H16. New products like You Li Tong and You Di Er have seen strong revenue growth of &gt;100% y/y, as have exported products to Africa which grew &gt;30%.</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;">5) &nbsp;&nbsp;&nbsp;Acquisition of Gland Pharma Limited, a key to the world. </span><span class="font2">Gland Pharma develops and manufactures generic injectables in therapeutic areas of antibiotics, oncology and cardiology and distributes them in more than 78 countries. It is the one of the largest global players in this market. Management expects more corporate resources sharing between Gland Pharma and Fosun in future, and Gland Pharma’s expertise and business know-how will upgrade the company's pharmaceutical R&amp;D business as well as accelerating its overseas expansion. The company will introduce clO insulin products via Gland Pharma to India where regulation on pharmacists is less stringent; they expected to generate Rmbl-2bn revenue. Also the company will introduce c20 products of Gland Pharma to China, each product is expected to generate &gt;Rmbl00mn revenue. In the near term, they will look for acquisition opportunities in US and Europe while solidifying their business in China, according to management.</span></p></li></ul>
<p><span class="font0" style="font-weight:bold;">4</span></p>
</body>
</html>